Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma
Jirapat Wonglhow, Panu Wetwittayakhlang, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Arunee Dechaphunkul · 2026
Read Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma by Jirapat Wonglhow, Panu Wetwittayakhlang, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Arunee Dechaphunkul (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13245436.txt.
Description
Jirapat Wonglhow and colleagues compare chemotherapy paths for a rare bile duct area cancer in a 2026 study. Ampullary cancer grows where the bile and pancreatic ducts meet the gut. Proof for the best first drug mix in advanced cases is scarce.
The team reviewed 97 patients treated at a university hospital in southern Thailand from 2005 to 2024. Among those who got drug care, gemcitabine-based mixes faced off against fluoropyrimidine-based ones. Survival with and without disease spread landed close for both families. Adding platinum raised tumor shrinkage but not survival. The authors suggest platinum mixes for patients who need fast shrinkage most.
Catalog record
| CREATOR | Jirapat Wonglhow, Panu Wetwittayakhlang, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Arunee Dechaphunkul |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |